Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 5.55%78.93B | 3.49%303.64B | 2.39%230.4B | 0.06%150.42B | -0.22%74.78B | 8.54%293.4B | 10.19%225.01B | 13.50%150.33B | 15.71%74.94B | 20.09%270.33B |
Operating revenue | 5.55%78.93B | 3.49%303.64B | 2.39%230.4B | 0.06%150.42B | -0.22%74.78B | 8.54%293.4B | 10.19%225.01B | 13.50%150.33B | 15.71%74.94B | 20.09%270.33B |
Other operating revenue | ---- | 21.59%2.03B | ---- | 3.77%772.19M | ---- | -25.71%1.67B | ---- | -28.27%744.17M | ---- | -27.21%2.25B |
Total operating cost | -1.21%65.88B | -2.01%259.67B | -2.48%198.67B | -4.74%130.15B | -1.23%66.68B | 9.47%265B | 11.92%203.71B | 17.79%136.63B | 19.25%67.51B | 19.96%242.07B |
Operating cost | -2.40%60.86B | -2.12%241.78B | -2.88%185.4B | -5.22%121.61B | -1.50%62.36B | 8.45%247.02B | 10.77%190.9B | 16.90%128.31B | 18.21%63.31B | 19.67%227.78B |
Operating tax surcharges | 44.36%1.77B | 19.97%5.82B | 20.83%4.19B | 21.49%2.71B | 9.61%1.23B | 13.65%4.85B | 12.85%3.47B | 7.43%2.23B | 17.03%1.12B | 23.35%4.27B |
Operating expense | 4.50%187.37M | -3.74%737.71M | -3.85%522.65M | 0.48%343.94M | 10.93%179.29M | 23.63%766.39M | 10.61%543.6M | 12.13%342.31M | 10.47%161.63M | 50.36%619.89M |
Administration expense | 21.23%2.17B | 2.74%7.73B | -4.81%5.15B | -3.33%3.42B | -0.06%1.79B | 20.08%7.52B | 22.60%5.41B | 22.59%3.54B | 23.85%1.79B | 18.02%6.26B |
Financial expense | -30.71%556.48M | -37.91%2.03B | -0.14%2.26B | -7.79%1.36B | -0.60%803.08M | 71.57%3.27B | 153.08%2.26B | 184.11%1.47B | 138.70%807.91M | 27.30%1.9B |
-Interest expense (Financial expense) | -22.43%940.46M | -7.61%4.55B | 0.16%3.61B | 4.28%2.49B | 6.44%1.21B | 42.92%4.92B | 58.17%3.6B | 82.53%2.39B | 116.39%1.14B | 63.11%3.44B |
-Interest Income (Financial expense) | 6.80%-524.68M | -32.59%-2.58B | -35.67%-1.88B | -38.01%-1.23B | -33.71%-562.96M | -43.49%-1.94B | -56.96%-1.39B | -69.87%-892.55M | -108.92%-421.02M | -77.89%-1.35B |
Research and development | 0.65%328.2M | 0.98%1.58B | 1.99%1.15B | -3.41%708.16M | -0.43%326.1M | 27.23%1.57B | 41.37%1.13B | 65.50%733.16M | 85.24%327.51M | 59.80%1.23B |
Credit Impairment Loss | -1,623.69%-22.89M | 80.96%-25.46M | -106.70%-6.33M | -84.31%13.05M | -155.13%-1.33M | 59.41%-133.72M | 270.58%94.41M | 341.64%83.15M | 54.64%2.41M | -156.98%-329.41M |
Asset Impairment Loss | -215.62%-21.86M | -88.72%-727.19M | -220.93%-117.84M | 19.21%-9.07M | 1,442.05%18.91M | -389.55%-385.33M | -290.55%-36.72M | 85.71%-11.22M | -111.13%-1.41M | 86.84%-78.71M |
Other net revenue | 111.43%2.09B | 37.58%4.86B | 36.22%4.12B | -15.67%1.72B | 28.17%988.76M | 31.31%3.53B | 1.78%3.02B | -9.51%2.04B | -6.90%771.44M | 50.89%2.69B |
Fair value change income | 674.25%478M | 5,192.68%948.45M | 5,640.17%1.01B | -429.01%-579.35M | -26.18%61.74M | 92.71%-18.62M | 103.60%17.56M | 1,602.84%176.09M | 273.34%83.63M | -10.19%-255.49M |
Invest income | 93.12%1.53B | 15.16%4.02B | 11.48%2.85B | 35.07%2.03B | 48.01%790.73M | 21.46%3.49B | -18.02%2.56B | -29.47%1.5B | -26.52%534.22M | 69.91%2.87B |
-Including: Investment income associates | 75.82%1.35B | 14.60%4.24B | 9.85%3.1B | -1.92%1.76B | -19.09%768.24M | -1.21%3.7B | 4.56%2.82B | -12.72%1.79B | 5.25%949.52M | 130.04%3.74B |
Asset deal income | -55.64%-10.26M | -26.70%27.35M | -68.47%5.83M | -205.03%-10.41M | -278.36%-6.59M | 815.07%37.31M | -34.88%18.49M | -67.03%9.91M | -107.13%-1.74M | 33.24%-5.22M |
Other revenue | 12.08%140.44M | 13.80%616.49M | 1.50%378.97M | -1.01%273.26M | -18.81%125.31M | 11.78%541.74M | 7.18%373.37M | 28.65%276.06M | 38.84%154.33M | 38.16%484.64M |
Operating profit | 66.74%15.14B | 52.89%48.83B | 47.39%35.85B | 39.64%21.98B | 10.70%9.08B | 3.20%31.94B | -3.30%24.32B | -15.89%15.74B | -8.67%8.2B | 23.36%30.95B |
Add:Non operating Income | -44.46%15.71M | 17.51%141.07M | 0.30%75.16M | 11.41%45.8M | 21.54%28.28M | 10.75%120.05M | 39.23%74.93M | 21.90%41.11M | 62.53%23.27M | -39.14%108.39M |
Less:Non operating expense | 67.02%469.06M | 15.72%889.99M | 30.95%597.83M | 85.06%442.17M | 140.23%280.83M | -27.52%769.11M | 38.50%456.53M | 32.31%238.93M | 36.26%116.9M | 125.40%1.06B |
Total profit | 66.37%14.69B | 53.66%48.08B | 47.56%35.33B | 38.87%21.59B | 8.86%8.83B | 4.32%31.29B | -3.77%23.94B | -16.29%15.55B | -8.99%8.11B | 20.97%29.99B |
Less:Income tax cost | 88.50%2.22B | 82.92%8.68B | 46.00%5.65B | 14.75%3.11B | -4.33%1.18B | -9.14%4.75B | -7.66%3.87B | -13.61%2.71B | -17.57%1.23B | 0.61%5.23B |
Net profit | 62.96%12.46B | 48.43%39.39B | 47.86%29.68B | 43.97%18.48B | 11.23%7.65B | 7.16%26.54B | -2.98%20.07B | -16.83%12.83B | -7.26%6.88B | 26.37%24.77B |
Net profit from continuing operation | 62.96%12.46B | 48.43%39.39B | 47.86%29.68B | 43.97%18.48B | 11.23%7.65B | 7.16%26.54B | -2.98%20.07B | -16.83%12.83B | -7.26%6.88B | 26.37%24.77B |
Less:Minority Profit | 65.55%2.3B | 35.46%7.34B | 36.18%5.32B | 34.00%3.39B | -3.28%1.39B | 14.71%5.42B | -2.83%3.91B | -9.62%2.53B | 11.12%1.44B | 20.33%4.73B |
Net profit of parent company owners | 62.39%10.17B | 51.76%32.05B | 50.68%24.36B | 46.42%15.08B | 15.05%6.26B | 5.38%21.12B | -3.01%16.16B | -18.43%10.3B | -11.14%5.44B | 27.88%20.04B |
Earning per share | ||||||||||
Basic earning per share | 60.92%0.383 | 51.25%1.21 | 50.08%0.923 | 46.80%0.574 | 14.98%0.238 | 5.26%0.8 | -3.15%0.615 | -18.54%0.391 | -11.16%0.207 | 26.67%0.76 |
Diluted earning per share | 57.98%0.376 | 50.00%1.2 | 49.11%0.917 | 46.55%0.573 | 14.98%0.238 | 5.26%0.8 | -3.15%0.615 | -18.54%0.391 | -11.16%0.207 | 26.67%0.76 |
Other composite income | -252.44%-4.33B | -18.54%3.47B | 43.18%4.8B | -24.61%3.94B | 108.96%2.84B | 17.24%4.25B | 48.86%3.36B | 729.93%5.23B | 4.44%1.36B | 285.23%3.63B |
Other composite income of parent company owners | -250.27%-4.19B | -15.40%3.27B | 58.87%4.93B | -18.67%3.85B | 104.73%2.79B | 35.72%3.87B | 76.25%3.1B | 550.26%4.74B | 4.56%1.36B | 104.17%2.85B |
Other composite income of minority owners | -380.47%-132.24M | -50.26%191.15M | -147.49%-121.1M | -81.48%91.5M | 1,039.47%47.15M | -50.57%384.28M | -48.48%255.02M | 122.94%494.02M | -54.71%-5.02M | 270.96%777.39M |
Total composite income | -22.40%8.14B | 39.18%42.86B | 47.19%34.48B | 24.11%22.42B | 27.34%10.49B | 8.44%30.79B | 2.12%23.43B | 23.72%18.06B | -5.51%8.24B | 38.24%28.4B |
Total composite income of parent company owners | -34.02%5.97B | 41.36%35.33B | 52.00%29.28B | 25.92%18.94B | 33.02%9.05B | 9.16%24.99B | 4.55%19.27B | 29.89%15.04B | -8.38%6.81B | 34.12%22.89B |
Total composite income of minority owners | 50.89%2.17B | 29.79%7.53B | 24.93%5.2B | 15.14%3.48B | 0.36%1.44B | 5.49%5.8B | -7.83%4.16B | 0.10%3.02B | 11.01%1.43B | 58.48%5.5B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.